Zentalis Pharmaceuticals Llc (ZNTL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zentalis Pharmaceuticals Llc (ZNTL) has a cash flow conversion efficiency ratio of -0.143x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.94 Million) by net assets ($216.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zentalis Pharmaceuticals Llc (ZNTL) defensive interval to measure how many days the company can operate on defensive assets alone.
Zentalis Pharmaceuticals Llc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Zentalis Pharmaceuticals Llc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zentalis Pharmaceuticals Llc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zentalis Pharmaceuticals Llc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beacon Lighting Group Ltd
AU:BLX
|
0.172x |
|
Soyea Technology Co Ltd
SHE:000909
|
0.022x |
|
Lexinfintech Holdings Ltd
NASDAQ:LX
|
0.081x |
|
Multilaser Industrial SA
SA:MLAS3
|
0.021x |
|
Grupa Azoty Zaklady Chemiczne Police SA
WAR:PCE
|
0.539x |
|
CASIN Real Estate Development Group Co Ltd
SHE:000838
|
0.093x |
|
TechTarget, Inc. Common Stock
NASDAQ:TTGT
|
-0.015x |
|
Econocom Group SA/NV
BR:ECONB
|
-0.130x |
Annual Cash Flow Conversion Efficiency for Zentalis Pharmaceuticals Llc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Zentalis Pharmaceuticals Llc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Zentalis Pharmaceuticals Llc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $216.20 Million | $-125.25 Million | -0.579x | -14.32% |
| 2024-12-31 | $337.19 Million | $-170.86 Million | -0.507x | -6.65% |
| 2023-12-31 | $437.39 Million | $-207.82 Million | -0.475x | -25.94% |
| 2022-12-31 | $434.02 Million | $-163.75 Million | -0.377x | +10.76% |
| 2021-12-31 | $364.48 Million | $-154.09 Million | -0.423x | -62.33% |
| 2020-12-31 | $333.38 Million | $-86.83 Million | -0.260x | +54.48% |
| 2019-12-31 | $68.42 Million | $-39.14 Million | -0.572x | +23.79% |
| 2018-12-31 | $32.31 Million | $-24.25 Million | -0.751x | -- |
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosert… Read more